We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$337M
AUM Growth
+$3.84M
Cap. Flow
-$22.8M
Cap. Flow %
-6.78%
Top 10 Hldgs %
34.36%
Holding
109
New
18
Increased
35
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$9.48M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.12M
3
CAH icon
Cardinal Health
CAH
+$6.74M
4
AGN
Allergan plc
AGN
+$5.18M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.64M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.87M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
CFNL
Cardinal Financial Corp
CFNL
+$5.03M
5
FRX
FOREST LABORATORIES INC
FRX
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
2 Financials 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$31.8B
$3.97M 1.18%
400,000
+84,848
+27% +$752K
TMO icon
27
Thermo Fisher Scientific
TMO
$217B
$3.89M 1.16%
33,000
-1,394
-4% -$164K
CVS icon
28
CVS Health
CVS
$122B
$3.77M 1.12%
50,000
-38,442
-43% -$2.91M
CLVS
29
DELISTED
Clovis Oncology, Inc.
CLVS
$3.73M 1.11%
+90,000
New +$4.64M
KERX
30
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$3.69M 1.1%
240,000
-25,325
-10% -$359K
HCA icon
31
HCA Healthcare
HCA
$89.3B
$3.38M 1%
60,000
-10,262
-15% -$541K
NKTR icon
32
Nektar Therapeutics
NKTR
$2.56B
$3.33M 0.99%
17,333
+5,213
+43% +$922K
CLDX icon
33
Celldex Therapeutics
CLDX
$3.26B
$3.25M 0.96%
13,267
+8,354
+170% +$1.89M
ELGX
34
DELISTED
Endologix Inc
ELGX
$3.12M 0.93%
20,500
+316
+2% +$42.1K
MYGN icon
35
Myriad Genetics
MYGN
$310M
$3.11M 0.92%
80,000
+55,432
+226% +$2.06M
CTRX
36
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$3.09M 0.92%
70,000
-10,880
-13% -$460K
ELV icon
37
Elevance Health
ELV
$85.5B
$3.01M 0.89%
28,000
-12,000
-30% -$1.24M
EW icon
38
Edwards Lifesciences
EW
$51.5B
$3M 0.89%
210,000
-67,122
-24% -$910K
PRXL
39
DELISTED
Parexel International Corp
PRXL
$2.91M 0.86%
55,000
+5,865
+12% +$294K
UHS icon
40
Universal Health Services
UHS
$10.5B
$2.87M 0.85%
30,000
+10,346
+53% +$894K
VAR
41
DELISTED
Varian Medical Systems, Inc.
VAR
$2.83M 0.84%
38,773
– –
RVNC
42
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.79M 0.83%
82,000
+32,865
+67% +$1.03M
STJ
43
DELISTED
St Jude Medical
STJ
$2.77M 0.82%
40,000
+5,606
+16% +$363K
LLY icon
44
Eli Lilly
LLY
$1.05T
$2.77M 0.82%
44,500
-8,958
-17% -$534K
NUVA
45
DELISTED
NuVasive, Inc.
NUVA
$2.7M 0.8%
76,000
-12,442
-14% -$426K
ABMD
46
DELISTED
Abiomed Inc
ABMD
$2.69M 0.8%
107,000
+17,084
+19% +$398K
CNC icon
47
Centene
CNC
$32.4B
$2.65M 0.79%
140,000
-48,676
-26% -$836K
LGND icon
48
Ligand Pharmaceuticals
LGND
$5.84B
$2.62M 0.78%
67,326
+3,900
+6% +$158K
UNH icon
49
UnitedHealth
UNH
$371B
$2.62M 0.78%
32,000
-30,979
-49% -$2.44M
ACHN
50
DELISTED
Achillion Pharmaceuticals
ACHN
$2.5M 0.74%
+330,000
New +$1.32M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
OC
Oarsman Capital Milwaukee, Wisconsin $806M AUM 19.96% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rhenman & Partners Asset Management held 109 positions worth $337M, up 1.2% from $333M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $22.8M in Q2 2014, closing 13 positions and reducing 37 holdings. Its most notable exit was Pfizer, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Vertex Pharmaceuticals worth $9.62M.

  • Rhenman & Partners Asset Management's largest Q2 2014 buy was Vertex Pharmaceuticals: 101,600 shares worth $9.62M.
  • Rhenman & Partners Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q2 2014, an estimated $9.48M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.87M.
  • Rhenman & Partners Asset Management fully exited Pfizer in Q2 2014, selling an estimated $11.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $337M portfolio in Q2 2014.
  • Rhenman & Partners Asset Management opened 18 new positions and closed 13 in Q2 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.2% quarter-over-quarter to $337M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.